Additionally, in the MCF-7/DOX cell line, we observed that the combination of metalloestrogens and aromatase inhibitors led to a decrease in the drug’s effectiveness due to an increase in the viability of breast cancer cells (both concentrations of letrozole and higher concentrations of exemestane). Here, CYP19A1 is linked to breast cancer.